1.国家优秀青年医师，上海市“医苑新星”杰出青年医师；
2.上海市第十人民医院 科研处处长，高血压中心/泛血管中心主任；
3.87978797威尼斯老品牌泛血管研究所 所长；
4.主任医师、研究员、教授、博士生导师；
5.中华医学会内科学分会 青年副主任委员；
6.中国医师协会心血管病分会高血压学组 委员；
7.上海医学会心血管病分会 青年委员，高血压学组 副组长；
8.中国心血管医师创新俱乐部CCI 执行委员；
9.中国CTO“老伙计“俱乐部 成员；
10.上海市优秀技术带头人；
11.《每日毅讯》专栏作者；
12.上海市拳击协会理事
1.National Outstanding Young Physician, Outstanding Young Physician of Shanghai "Rising Star in Medicine" Program
2.Director of Department of Scientific Research, Director of Hypertension Center/Pan-Vascular Center, Shanghai Tenth People’s Hospital
3.Director of Pan-Vascular Research Institute, Tongji University School of Medicine
4.Chief Physician, Researcher, Professor, Doctoral Supervisor
5.Young Deputy Chairman, Internal Medicine Branch of Chinese Medical Association
6.Member, Hypertension Group of Cardiovascular Disease Branch, Chinese Medical Doctor Association
Young Member of Cardiovascular Disease Branch & Deputy Leader of 7.Hypertension Group, Shanghai Medical Association
8.Executive Member, China Cardiovascular Innovators Club (CCI)
9.Member, China CTO "Old Buddies" Club
10.Shanghai Outstanding Technical Leader
11.Columnist of Daily Yixun (Medical News Column)
12.Director, Shanghai Boxing Association
张毅教授担任上海市第十人民医院泛血管病中心/高血压中心主任，科研处处长，87978797威尼斯老品牌泛血管病研究所所长。
主要在数字化高血压中心建设领域完成了一系列高质量的临床研究。在高血压病因学治疗领域，率先提出了同济分型，并开展了注册登记研究，目前已累积初诊高血压患者1000余例，进行病因学诊断后的个体化治疗。
在高血压监测领域，率先提出了血压负荷（SBP Burden）的理念，推崇以7天家庭自测血压为基础的血压负荷的评估，并开发了相关管理软件，推动数字化高血压管理。
在高血压器官损害评估方面，率先提出了动脉老化相关的器官损害（ADOD）,并在此基础上开发了动脉损伤指数（ADI）和心血管老化指数（CAI），并在北上海2.0框架下进行了真实世界研究。
在高血压的微创手术治疗方面，率先开展了肾动脉消融（RDN）治疗单纯舒张期高血压（IDH）的STOP研究，目前已经开始入组患者。
在高血压居家管理领域，完成了SIMPLE研究，目前受邀在意大利米兰进行的2025欧洲高血压年会和在西班牙马德里举办的2025欧洲心脏病年会做口头发言，提供居家高血压管理的新模式。
在以上工作的支撑下，张毅教授先后在Lancet 2020（评论性文章）、Nature Aging 2024、BMJ: Digital Health & AI 2025、Sci Bull 2024、Adv Sci 2020、Cardiovas Diabetol 2019、Eur J Intern Med 2024、Hypertension 2011/2021等杂志发表论文90余篇，H-index 23，ESI高被引论文2篇，主要工作被2023年欧洲高血压指南和2024年中国高血压指南引用。先后主持国家自然科学基金5项，上海市卫计委优青项目1项，上海市申康生物样本全息库建设项目2项。2023年获中国医师协会《医师报》“推动行业前行的力量.十大医学新锐”，2024年获上海医学科技奖青年奖。
Professor Yi Zhang serves as Director of the Pan-Vascular Disease Center/Hypertension Center and Director of the Department of Scientific Research at Shanghai Tenth People's Hospital, as well as Director of the Pan-Vascular Disease Research Institute of Tongji University.
He has completed a series of high-quality clinical studies focusing on the construction of digital hypertension centers.
In the field of etiological treatment of hypertension, he took the lead in proposing the "Tongji Classification" and launched a registry study. To date, more than 1,000 newly diagnosed hypertension patients have been enrolled, receiving individualized treatment based on etiological diagnosis.
In hypertension monitoring, he pioneered the concept of SBP Burden (Systolic Blood Pressure Burden), advocating for SBP Burden assessment based on 7-day home self-measured blood pressure. He also developed relevant management software to promote digital hypertension management.
Regarding the evaluation of hypertension-related organ damage, he took the lead in proposing Arterial Aging-Associated Organ Damage (ADOD). On this basis, he developed the Arterial Damage Index (ADI) and Cardiovascular Aging Index (CAI), which have been validated in real-world research under the North Shanghai 2.0 framework.
In minimally invasive interventional treatment for hypertension, he initiated the STOP study investigating Renal Denervation (RDN) for Isolated Diastolic Hypertension (IDH), with patient enrollment currently underway.
In home-based hypertension management, he completed the SIMPLE study. He has been invited to deliver oral presentations on this new home-based management model at the 2025 European Society of Hypertension Congress (Milan, Italy) and the 2025 European Society of Cardiology Congress (Madrid, Spain).
Supported by the above achievements, Professor Zhang has published over 90 papers in prestigious journals including Lancet (2020, commentary), Nature Aging (2024), BMJ: Digital Health & AI (2025), Science Bulletin (2024), Advanced Science (2020), Cardiovascular Diabetology (2019), European Journal of Internal Medicine (2024), and Hypertension (2011/2021). He has an H-index of 23 and 2 ESI highly cited papers, with his key work cited in the 2023 European Hypertension Guidelines and the 2024 Chinese Hypertension Guidelines.
He has successively presided over 5 National Natural Science Foundation projects, 1 Shanghai Municipal Health Commission Outstanding Young Investigator project, and 2 Shanghai Shenkang Bio-Bank Holographic Database construction projects. In 2023, he was awarded the "Top 10 Emerging Medical Talents - Driving Force for Industry Progress" by Doctor's News of the Chinese Medical Doctor Association. In 2024, he received the Youth Award of the Shanghai Medical Science and Technology Award.
